Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2014 08:01 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer

CAMBRIDGE, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug...
May 06, 2014 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports First Quarter 2014 Financial Results

CAMBRIDGE, Mass., May 6, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2014. For the first quarter...
May 02, 2014 08:47 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform

CAMBRIDGE, Mass., May 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
April 30, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences

CAMBRIDGE, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
April 15, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
February 24, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 34th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
February 10, 2014 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results

CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2013. For the...
February 05, 2014 08:30 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the 2014 Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
January 21, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
December 12, 2013 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business

CAMBRIDGE, Mass., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) announced today that it has named Michael Franken, M.D. as President, Biosimilars Business. Dr. Franken...